⌘K
t
| Date | 31 Jan 2023 |
| Time | 11:15:50 |
| Category | AGMs and other meetings |
| ID | 4273O |
31 January 2023
SkinBioTherapeutics plc
Results of General Meeting
SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's General Meeting, held yesterday 30 January 2023, all resolutions were duly passed.
Details of the proxy votes received on each resolution by the Company's Registrar are set out below:
|
Resolution |
For & Discretionary |
Against |
Withheld |
|||||
|
|
Number of votes |
% |
Number of votes |
% |
Number of votes |
% |
||
|
1 |
The Directors' and Auditors' reports and the financial statements for the financial year ended 30 June 2022 be received and adopted |
36,364,572 |
99.58% |
117,330 |
0.32% |
37,825 |
0.10% |
|
|
2 |
Jeffreys Henry LLP be re-appointed as the auditors of the Company until the next Annual General Meeting of the Company |
36,362,147 |
99.57% |
129,755 |
0.36% |
27,825 |
0.08% |
|
|
3 |
The Directors be authorised to fix the auditors' remuneration |
36,377,487 |
99.61% |
114,415 |
0.31% |
27,825 |
0.08% |
|
|
4 |
To authorise the directors to allot shares |
36,295,269 |
99.39% |
193,322 |
0.53% |
31,136 |
0.09% |
|
|
5 |
Special resolution to authorise the directors to disapply pre-emption rights |
36,257,227 |
99.28% |
232,575 |
0.64% |
29,925 |
0.08% |
|
|
6 |
Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment |
36,310,509 |
99.43% |
178,555 |
0.49% |
30,663 |
0.08% |
|
-Ends-
For more information, please contact:
|
SkinBioTherapeutics plc |
Tel: +44 (0) 191 495 7325 |
|
Cenkos Securities Plc (Nominated Adviser & Broker) |
Tel: +44 (0) 20 7397 8900 |
|
Instinctif Partners (financial press) |
Tel: +44 (0) 20 7457 2020 |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps™, a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com.